Henry Meds' advertised "$179" headline doesn't apply to its most commonly prescribed tirzepatide product — the real price is $349-$449/month depending on format, plus an active Eli Lilly lawsuit over marketing practices worth knowing about.
Luma Health's compounded tirzepatide is $297/month, flat, clearly stated upfront.
Henry Meds is a real, four-year-old telehealth company with a large customer base, and it's worth reviewing honestly — both what it does well and what's worth knowing before signing up, particularly around tirzepatide specifically.
The Real Price Behind the Headline
Henry Meds' marketing commonly advertises pricing "starting at $179," but that figure applies to liraglutide or long-commitment prepay plans, not the tirzepatide most patients actually sign up for. Compounded oral tirzepatide runs approximately $349/month, and injectable compounded tirzepatide runs approximately $449/month, with pricing not consistently displayed across the site — some pages require completing an intake quiz or scheduling a consultation to see a quote at all.
What's Included
Henry Meds' pricing is cash-pay only (no insurance accepted) and includes provider visits, medication, and supplies like alcohol swabs, billed monthly while medication typically ships in 10-11 week batches. The model is deliberately no-frills — a licensed-provider evaluation and prescription, without a structured coaching curriculum layered on top, which is a genuine feature for patients who want medication without paying for coaching, and a gap for patients who want built-in behavioral support.
The Eli Lilly Lawsuit
Henry Meds faces an active lawsuit filed by Eli Lilly in April 2025, alleging marketing practices similar to those the FDA flagged in warning letters sent to other GLP-1 compounders industry-wide — including referencing branded-drug clinical trial data and selling tirzepatide in oral forms not FDA-approved in that format. As of this writing, Henry Meds has not received a public FDA warning letter itself, and continues to operate. This sits within the same broader industry-wide compounding regulatory shift discussed elsewhere: the tirzepatide shortage was resolved in December 2024, narrowing the legal basis for routine cost-driven compounding across the market.
Henry Meds holds a strong Trustpilot rating (4.5/5 across 12,000+ reviews) but a poor BBB grade, driven specifically by complaints about auto-renewal billing and difficulty cancelling non-refundable prepay plans. The pharmacy fulfilling prescriptions is named on request and on the shipping label, which is a positive transparency signal worth confirming with any compounding provider.
How the Cost Compares
Henry Meds' injectable tirzepatide at $449/month month-to-month, or its oral tirzepatide at $349/month, both run higher than Luma Health's flat $297/month tirzepatide, which doesn't require a long-term prepay commitment to access. If Henry Meds' 12-month prepay pricing is lower for your specific product, weigh that against the non-refundable commitment structure before committing.
Who Henry Meds Fits Best
- Specifically want oral tirzepatide or microdose format options
- Don't want bundled behavioral coaching
- Are comfortable with a non-refundable prepay commitment for the lowest rate
- Want the price clearly stated upfront, not hidden behind an intake quiz
- Prefer month-to-month flexibility over a prepay commitment
- Want a lower price without needing a long-term commitment
One clear price,
no intake quiz required to see it
Compounded tirzepatide at $297/month, flat, month-to-month — medical evaluation, provider visits, and shipping all included.
Get Started → Or start your free health assessmentFrequently Asked Questions
Not for the tirzepatide most patients sign up for. The $179 figure applies to liraglutide or long-commitment prepay plans; injectable tirzepatide is approximately $449/month and oral tirzepatide approximately $349/month.
No. Henry Meds is cash-pay only, with no insurance billing for compounded products.
Filed in April 2025, it alleges marketing practices similar to those the FDA flagged in industry-wide warning letters, including referencing branded clinical trial data and selling tirzepatide in non-FDA-approved oral forms.
Yes, it's an operating telehealth company with licensed providers and a named compounding pharmacy. It has not received a public FDA warning letter, though it faces the Eli Lilly lawsuit and a poor BBB grade tied to billing complaints.
Generally no — prepay plans are described as non-refundable, which is a significant commitment to weigh before choosing a multi-month plan for the lower rate.
Luma Health's compounded tirzepatide is $297/month, flat, month-to-month — lower than Henry Meds' month-to-month rate for either format, without requiring a non-refundable prepay commitment.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
- Better Business Bureau. Henry Meds business profile. BBB.org. 2026.
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov